

Matching-Adjusted Indirect Treatment Comparison of Sotorasib vs Adagrasib for Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation (20240246)

First published: 22/11/2024

Last updated: 20/02/2026

Study

Finalised

Administrative details

EU PAS number

EUPAS1000000380

Study ID

1000000380

DARWIN EU® study

No

Study countries

United States

Study status

Finalised

Research institutions and networks

Institutions

Amgen Inc.

Contact details

Study institution contact

Global Development Leader Amgen Inc.

medinfo@amgen.com

Study contact

medinfo@amgen.com

Primary lead investigator

Global Development Leader Amgen Inc.

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 15/09/2024

Actual: 24/09/2024

Study start date

Planned: 29/11/2024

Actual: 26/11/2024

Data analysis start date

Planned: 29/11/2024

Actual: 26/11/2024

Date of interim report, if expected

Planned: 31/12/2024

Date of final study report

Planned: 30/09/2025

Actual: 23/10/2025

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

This study is being funded by Amgen Inc.

Study protocol

[Protocol-Published Original sotorasib 20240246.pdf \(1.93 MB\)](#)

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study topic:

Disease /health condition

Human medicinal product

Study type:

Clinical trial

Scope of the study:

Safety study (incl. comparative)

Study drug and medical condition

Study drug International non-proprietary name (INN) or common name

SOTORASIB

ADAGRASIB

Anatomical Therapeutic Chemical (ATC) code

(L01XX73) sotorasib

sotorasib

(L01XX77) adagrasib

adagrasib

Medical condition to be studied

Non-small cell lung cancer recurrent

Documents

Study results

[20240246 ORSR.pdf](#) (76.73 KB)

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

[Clinical trial](#)

[Published literature](#)

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Yes

Check completeness

Yes

Check stability

Yes

Check logical consistency

Yes

Data characterisation

Data characterisation conducted

Yes